Table 2.
Association between sex and the dispensing of combined lipid- and blood pressure-lowering medications at 3-, 6-, 9- and 12-months following hospital admission for myocardial infarction, stroke/transient ischaemic attack, Australia, 2012–2017.
| Neither medication |
Both medications |
|||
|---|---|---|---|---|
| % (n) | RR (95% CI)1 | % (n) | RR (95% CI) | |
| CVD medication dispensed at 3-months following index event (n = 8,278) | ||||
| Male | 13 (641) | 1.00 (ref) | 58 (2,873) | 1.00 (ref) |
| Female | 16 (536) | 1.19 (1.07, 1.32) | 51 (1,676) | 0.91 (0.87, 0.95) |
| CVD medication dispensed at 6-months following index event (n = 7,690) | ||||
| Male | 14 (669) | 1.00 (ref) | 56 (2,598) | 1.00 (ref) |
| Female | 18 (549) | 1.21 (1.09, 1.34) | 49 (1,512) | 0.90 (0.86, 0.94) |
| CVD medication dispensed at 9-months following index event (n = 7,195) | ||||
| Male | 16 (675) | 1.00 (ref) | 55 (2,372) | 1.00 (ref) |
| Female | 19 (533) | 1.16 (1.05, 1.29) | 49 (1,398) | 0.91 (0.87, 0.95) |
| CVD medication dispensed at 12-months following index event (n = 6,703) | ||||
| Male | 17 (676) | 1.00 (ref) | 53 (2,154) | 1.00 (ref) |
| Female | 19 (518) | 1.14 (1.03, 1.26) | 48 (1,296) | 0.92 (0.88, 0.97) |
1
Analyses adjusted for age, education, type of CVD event, history of prior CVD, and patient concession status.